Fulcrum Therapeutics (FULC) Current Assets (2018 - 2026)

Fulcrum Therapeutics (FULC) has reported Current Assets for 9 consecutive years, with $322.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Current Assets rose 47.17% year-over-year to $322.9 million; the TTM figure through Jun 2026 stood at $322.9 million (up 47.17% YoY), while the FY2025 annual figure was $357.5 million, up 43.04% from the prior year.
• Current Assets declined to $322.9 million in Q2 2026 per FULC's latest filing, from $338.7 million in the prior quarter.
• Across five years, Current Assets topped out at $357.5 million in Q4 2025 and bottomed at $174.2 million in Q2 2022.
• Historically, Current Assets has averaged $255.1 million across 5 years, with a median of $246.1 million in 2023.
• Annual changes were most pronounced in 2023 — Current Assets jumped 62.38% — and 2024, when it retreated 28.03%.
• Fulcrum Therapeutics' Current Assets stood at $207.5 million in 2022, then climbed by 16.71% to $242.2 million in 2023, then rose by 3.19% to $249.9 million in 2024, then surged by 43.04% to $357.5 million in 2025, then dropped by 9.69% to $322.9 million in 2026.
• Business Quant data shows FULC's Current Assets at $322.9 million in Q2 2026, $338.7 million in Q1 2026, and $357.5 million in Q4 2025.